特別企画
認知症疾患修飾薬に関する意識と実態に関する神経治療学会会員調査
キーワード:
disease modifying therapy (DMT),
Alzheimer disease,
amyloid β,
positron emission tomography (PET),
cerebrospinal fluid
2024 年 41 巻 3 号 p. 206-212
詳細
2024 年 41 巻 3 号 p. 206-212
In introducing disease modifying therapy (DMT) for Alzheimer disease, Japanese Society for Neurological Therapeutics (JSNT) has investigated online survey for JSNT menbers concerning on recognition and present status of DMT. Ninty eight % of the response was obtained from neurologist and the response rare was 48.9% (298/609). Majority of instituitututions planed to introduce DMT (63%), and select amyloid PET (77%) as as a diagnostic method. This survey may provide a useful tool for facilitating introduction of DMT for Alzheimer disease in Japan.
